核苷类似物处方对乙型肝炎对肝癌在香港的发病率的影响：

StephenW

Aliment Pharmacol Ther. 2016 Dec 15. doi: 10.1111/apt.13895. [Epub ahead of print]
Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.Seto WK1,2, Lau EH3, Wu JT3, Hung IF1, Leung WK1, Cheung KS1, Fung J1,2, Lai CL1,2, Yuen MF1,2.
Author information

AbstractBACKGROUND: The temporal relationship between nucleoside analogue (NA) therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level.
AIM: To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB-prevalent region.
METHODS: We obtained territory-wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population-based liver cancer incidence data from 1990 to 2012. We compared the liver cancer incidences from 1990 to 1998 and 1999 to 2012 with adjustment for local hepatitis B surface antigen seroprevalence.
RESULTS: Nucleoside analogue prescription patient headcount increased from 2006 per year in 1999 to 26 411 in 2012. Prescription volume in 2012 was highest among 55-64 years (30.3%), higher than 65-74 years (13.0%) and ≥75 years (5.8%). Age-standardised liver cancer incidence 1999-2012 decreased by 1.88%/year (95% CI 3.34% to 0.42%/year). NA therapy was associated with decline in age-adjusted liver cancer incidence (2.7 per 100 000 persons, P < 0.001, 95% CI 1.4-4.0 per 100 000 persons). Fifty-five to sixty-four years age group had the most significant decline (men: 24.0 per 100 000 persons, P = 0.001, 95% CI 11.4-36.6 per 100 000 persons; women: 8.5 per 100 000 persons, P = 0.009, 95% CI 2.3-14.6 per 100 000 persons). No significant association was noted in age groups 65-74 years and ≥75 years (both P > 0.05).
CONCLUSIONS: Nucleoside analogue prescription was associated with a reduction of overall liver cancer incidence in a CHB-prevalent region. The lack of association among individuals of ≥65 years was consistent with the low nucleoside analogue prescription volume in elderly patients, mitigating the impact of CHB treatment on liver cancer.

© 2016 John Wiley & Sons Ltd.

PMID:27976416DOI:10.1111/apt.13895

StephenW

Aliment Pharmacol Ther。 2016 Dec 15。doi：10.1111 / apt.13895。 [打印前的电子版]
核苷类似物处方对乙型肝炎对肝癌在香港的发病率的影响：一个领域的生态研究。
Seto WK1,2，Lau EH3，Wu JT3，Hung IF1，Leung WK1，Cheung KS1，Fung J1,2，Lai CL1,2，Yuen MF1,2。
作者信息
抽象
背景：

尚未在群体水平上评估用于慢性乙型肝炎（CHB）的核苷类似物（NA）治疗与肝癌发展之间的时间关系。
目标：

调查核苷类似物处方对CHB流行地区肝癌发病率的影响。
方法：

我们从1999年（当时首次在香港提供核苷类似物，到2012年）和从1990年到2012年的基于人群的肝癌发病率数据获得了全境核苷类似物处方数据。我们比较了1990年至1998年和1999年的肝癌发病率到2012年，调整局部乙型肝炎表面抗原血清阳性率。
结果：

核苷类似物处方患者人数从1999年的2006年增加到2012年的26 411人。2012年处方量在55-64岁（30.3％），高于65-74岁（13.0％）和≥75岁（5.8岁） ％）。 1999 - 2012年的年龄标准化肝癌发病率下降了1.88％/年（95％CI 3.34％至0.42％/年）。 NA治疗与年龄校正的肝癌发病率下降相关（2.7 / 10万人，P <0.001，95％CI 1.4-4.0 / 10万人）。男性：24.0 / 10万人，P = 0.001,95％CI 11.4-36.6 / 10万人;女性：8.5 / 10万人，P = 0.009 ，95％CI 2.3-14.6 / 10万人）。在65-74岁和≥75岁的年龄组没有显着关联（P> 0.05）。
结论：

核苷类似物处方与CHB-普遍区域中总体肝癌发生率的降低相关。 ≥65岁的个体之间缺乏关联与老年患者的低核苷类似物处方体积一致，减轻CHB治疗对肝癌的影响。

©2016 John Wiley＆Sons Ltd.

PMID：
    27976416
DOI：
    10.1111 / apt.13895

MP4

恩替卡韦FDA要求的十年追踪研究还在做
http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm